Design, synthesis and immunological evaluation of 1,2,3-triazole-tethered carbohydrate–Pam 3 Cys conjugates as TLR2 agonists

Nalla, Naresh; Pallavi, Preethi M. C.; Bonam, Srinivasa Reddy; Miryala, Sreekanth; Kumar, V. Senthil; Mahboob, M.; Halmuthur, M. Sampath Kumar

doi:10.1016/j.bmc.2015.06.070

Cited by 20 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After administering the glycopeptide immunogen to rabbits without any additional adjuvants, a glycan-dependent antibody can be produced in a short period of time, and the induced serum antibodies can recognize a wide-range of HIV-1 gp120s across different clades (Cai et al, 2017). Pam2Cys and Pam3Cys are also molecular adjuvants used in vaccines (Zaman & Toth, 2013; McDonald, Byrne & Payne, 2015; Nalla et al, 2015) (Table 2; Fig. 3).…”

Section: Toll-like Receptor Agonists As Built-in Adjuvantsmentioning

confidence: 99%

Application of built-in adjuvants for epitope-based vaccines

Yao

Zhao

Shao

et al. 2019

PeerJ

View full text Add to dashboard Cite

Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: (1) pattern recognition receptor ligands (i.e., toll-like receptors); (2) virus-like particle carrier platforms; (3) bacterial toxin proteins; and (4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles, lipid core peptides, and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

show abstract

Section: Toll-like Receptor Agonists As Built-in Adjuvantsmentioning

confidence: 99%

Application of built-in adjuvants for epitope-based vaccines

Yao

Zhao

Shao

et al. 2019

PeerJ

View full text Add to dashboard Cite

show abstract

“…After administering the glycopeptide immunogen to rabbits without any additional adjuvants, a glycan-dependent antibody can be produced in a short period of time, and the induced serum antibodies can recognize a wide-range of HIV-1 gp120s across different clades (Cai et al, 2017). Pam2Cys and Pam3Cys are also molecular adjuvants used in vaccines (Zaman & Toth, 2013;McDonald et al, 2015;Nalla et al, 2015) (Table 2; Fig.3). Synthetic lipopeptides and their analogues play an important role in the study of built-in adjuvants for epitope-based vaccines.…”

Section: Mcdonald Et Al Constructed a Variety Of Self-adjuvating Mucmentioning

confidence: 99%

Peer Review #3 of "Application of built-in adjuvants for epitope-based vaccines (v0.1)"

Banday¹

2019

View full text Add to dashboard Cite

Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: 1) pattern recognition receptor (PRR) ligands (i.e., toll-like receptors [TLRs]); 2) virus-like particle (VLP) carrier platforms; 3) bacterial toxin proteins; and 4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles [SAPNs], lipid core peptides [LCPs], and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

show abstract

“…However, with the increase of complexity of glycopeptide moieties by introducing the helper T cell epitope, their coupling with the lipopeptide carrier has become more difficult. Many approaches to achieve glycopeptides conjugation with Pam 3 Cys, including preinstallation of molecular handles such as alkyne or active ester, in the Pam 3 Cys moiety have been described [ 40 , 41 , 42 , 43 , 44 , 45 ]. In the Boons group, native chemical ligation (NCL) was brought into the synthesis of three-component vaccine 19 ( Scheme 3 ) [ 46 , 47 ].…”

Section: Lipopeptides As Carrier Molecules or Adjuvants For Vaccinmentioning

confidence: 99%

Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines

Guo

2018

Molecules

View full text Add to dashboard Cite

Many malignant cell surface carbohydrates resulting from abnormal glycosylation patterns of certain diseases can serve as antigens for the development of vaccines against these diseases. However, carbohydrate antigens are usually poorly immunogenic by themselves, thus they need to be covalently coupled with immunologically active carrier molecules to be functional. The most well established and commonly used carriers are proteins. In recent years, the use of toll-like receptor (TLR) ligands to formulate glycoconjugate vaccines has gained significant attention because TLR ligands can serve not only as carrier molecules but also as built-in adjuvants to form fully synthetic and self-adjuvanting conjugate vaccines, which have several advantages over carbohydrate-protein conjugates and formulated mixtures with external adjuvants. This article reviews recent progresses in the development of conjugate vaccines based on TLR ligands. Two major classes of TLR ligands, lipopeptides and lipid A derivatives will be covered with more focus on monophosohoryl lipid A (MPLA) and related analogs, which are TLR4 ligands demonstrated to be able to provoke T cell-dependent, adaptive immune responses. Corresponding conjugate vaccines have shown promising application potentials to multiple diseases including cancer.

show abstract

Design, synthesis and immunological evaluation of 1,2,3-triazole-tethered carbohydrate–Pam 3 Cys conjugates as TLR2 agonists

Cited by 20 publications

References 20 publications

Application of built-in adjuvants for epitope-based vaccines

Application of built-in adjuvants for epitope-based vaccines

Peer Review #3 of "Application of built-in adjuvants for epitope-based vaccines (v0.1)"

Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines

Contact Info

Product

Resources

About